Optimi Health has announced the successful production and quality release of a new batch of five milligram psilocybin capsules, marking a significant step forward for both clinical research and patient access. Manufactured at the company’s specialized facility in Princeton, British Columbia, these naturally derived capsules were produced under strict current good manufacturing practice standards. The move allows the company to streamline its operations by using a single high-quality batch for two distinct purposes across different continents.
A primary focus for this latest shipment is a Health Canada authorized Phase II study targeting major depressive disorder. This multi site trial will involve up to two hundred participants who will each receive a single supervised dose of the compound. Researchers hope that the resulting safety and efficacy data will provide the necessary evidence to seek formal registration for psilocybin assisted therapy in Canada and other global markets by the time dosing concludes in late 2027.
Simultaneously, Optimi is expanding its footprint in Australia, where these same capsules are being supplied to licensed clinics through the Therapeutic Goods Administration’s Authorised Prescriber Scheme. In this region, the medication is specifically prescribed for those suffering from treatment resistant depression. To make the therapy more accessible, various public and private payers have stepped in to reimburse treatment costs, including organizations like Medibank and the US Department of Veterans Affairs.
Dane Stevens, CEO and co founder of Optimi Health, emphasized the strategic advantage of handling everything from encapsulation to testing within their own licensed facility. He noted that having an identical formulation for both commercial use in Australia and clinical trials in Canada simplifies the regulatory process significantly since they already own the supporting chemistry and manufacturing files. While excitement grows around these developments, the company maintains that psilocybin remains under investigation for major depressive disorder and has not yet received full market authorization from Health Canada.
